Onconova Therapeutics Inc (ONTX.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2006||Chairman of the Board|
|59||1998||President, Chief Executive Officer, Director|
|47||2016||Chief Financial Officer|
|64||2015||Senior Vice President - Research and Development, Chief Medical Officer|
|52||2005||Senior Vice President - Product Development|
- BRIEF-Oleg Nodelman Reports 9.99 Pct Passive Stake In Onconova Therapeutics As Of April 27, 2018
- BRIEF-Onconova Therapeutics Announces Pricing Of $25 Mln Upsized Underwritten Public Offering
- BRIEF-Onconova Says As Of April 13, Co Was Not Able To Regain Compliance With Continued Listing Requirements Of Nasdaq Capital Market
- BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting
- BRIEF-Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants